SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia

[1]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[2]  E. Pasmant,et al.  Review and update of SPRED1 mutations causing legius syndrome , 2012, Human mutation.

[3]  A. Burlingame,et al.  A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. , 2012, Genes & development.

[4]  R. Morita,et al.  miR126 positively regulates mast cell proliferation and cytokine production through suppressing Spred1 , 2011, Genes to cells : devoted to molecular & cellular mechanisms.

[5]  D. Lipka,et al.  FLT3 as a therapeutic target in AML: still challenging after all these years. , 2010, Blood.

[6]  E. Estey,et al.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. , 2010, Blood.

[7]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[8]  M. Bergo,et al.  Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. , 2009, Blood.

[9]  Ching-Hon Pui,et al.  Germline genomic variants associated with childhood acute lymphoblastic leukemia , 2009, Nature Genetics.

[10]  R. Levine.  Inherited susceptibility to pediatric acute lymphoblastic leukemia , 2009, Nature Genetics.

[11]  E. Papaemmanuil,et al.  Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia , 2009, Nature Genetics.

[12]  G. Leverger,et al.  SPRED1 disorder and predisposition to leukemia in children. , 2009, Blood.

[13]  E. Pasmant,et al.  SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype , 2009, Journal of Medical Genetics.

[14]  A. Hall,et al.  Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. , 2008, Cancer research.

[15]  K. Shannon,et al.  Targeting Ras in Myeloid Leukemias , 2008, Clinical Cancer Research.

[16]  C. Preudhomme,et al.  Cooperating gene mutations in acute myeloid leukemia: a review of the literature , 2008, Leukemia.

[17]  G. Thomas,et al.  Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype , 2007, Nature Genetics.

[18]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[19]  U. Walter,et al.  The VASP-Spred-Sprouty Domain Puzzle* , 2006, Journal of Biological Chemistry.

[20]  Takafumi Yoshida,et al.  Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors , 2006, Oncogene.

[21]  B. Neel,et al.  Stops along the RAS pathway in human genetic disease , 2006, Nature Medicine.

[22]  F. Porteu,et al.  B56‐containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX‐1 and ERK , 2006, The EMBO journal.

[23]  D. Christiansen,et al.  Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia , 2005, Leukemia.

[24]  M. Kubo,et al.  Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness , 2005, The Journal of experimental medicine.

[25]  A. Yoshimura,et al.  Spred-1 Negatively Regulates Interleukin-3-mediated ERK/Mitogen-activated Protein (MAP) Kinase Activation in Hematopoietic Cells* , 2004, Journal of Biological Chemistry.

[26]  A. Yoshimura,et al.  The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization , 2004, Oncogene.

[27]  B. Gelb,et al.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. , 2004, Blood.

[28]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[29]  R. Baron,et al.  Spred is a Sprouty-related suppressor of Ras signalling , 2001, Nature.

[30]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[31]  G. Knowles.  Europe against cancer programme — Overview of advancing cancer nursing practice project , 1999 .

[32]  G. Leverger,et al.  Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia , 2010, Leukemia.

[33]  A. Fanaroff.  Clinical and Mutational Spectrum of Neurofibromatosis Type 1–like Syndrome , 2010 .